Molbio Diagnostics IPO GMP Today: Date, Price, and Listing Date
Molbio Diagnostics IPO opens on 10 August 2026. Here's a look at its GMP, financial performance, valuation, peer comparison, and key risks.
Molbio Diagnostics IPO GMP Overview: Molbio Diagnostics IPO, worth ₹939.70 Cr, will open for subscription from 10 Aug to 12 Aug 2026. Molbio Diagnostics allotment is expected on 13 Aug, and shares are likely to be listed on BSE & NSE on 17 Aug 2026. The price band for Molbio Diagnostics IPO is set between ₹768 to ₹807.
Molbio Diagnostics IPO GMP: Molbio Diagnostics develops and manufactures diagnostic testing devices used to detect infectious and other diseases. Its flagship Truenat platform is a portable testing machine that delivers results in about an hour.
Molbio Diagnostics is set to launch a ₹939.70 crore mainboard IPO through a combination of a fresh issue of shares and an offer for sale (OFS). Here are the key details of the issue.
Molbio Diagnostics IPO Details
Here are the listing dates and important details investors should know about the upcoming Mainboard IPO in Aug.
-
Molbio Diagnostics IPO is worth ₹939.70 cr, and the issue is a combination of a fresh issue of ₹ 200 cr and offer for sale of ₹739.70 cr.
-
Molbio Diagnostics IPO will open for subscription on 10 Aug 2026 and close on 12 Aug 2026. The price band is set between ₹768 to ₹807
-
Molbio Diagnostics IPO’s allotment is likely to take place on 13 Aug 2026 and the shares are expected to be listed on BSE and NSE on 17 Aug 2026.
-
Promoters currently hold 46.65%, which will come down to 43.01% after the listing.
-
Kfin Technologies will be the registrar for the Molbio Diagnostics IPO.
|
Parameter |
Detail |
|---|---|
|
IPO Open Date |
10 Aug 2026 |
|
IPO Close Date |
12 Aug 2026 |
|
Expected Allotment Date |
13 Aug 2026 |
|
Expected Listing Date |
17 Aug 2026 (BSE & NSE) |
|
Price Band |
₹768 to ₹807 per share |
|
Lot Size |
18 shares |
|
Minimum Investment |
₹14,526 |
|
Fresh Issue |
₹200.00Cr |
|
Offer for Sale (OFS) |
₹739.70Cr |
|
Total Issue Size |
₹939.70Cr |
Molbio Diagnostics IPO GMP Today
Molbio Diagnostics IPO GMP today (6th Aug 2026) stands at ₹170, up 21.07% from its upper price band of ₹807 in the grey market (as per investor gain). GMP figures change daily based on market sentiment and demand for the IPO.
GMP figures are for news purposes only. We neither trade nor recommend trading in the grey market.
Investors should note grey market premium is unofficial & not regulated by SEBI. GMP reflects only informal market trends and should not be considered a reliable indicator of listing gains.
READ THIS ALSO: Leap India IPO GMP Today
About Molbio Diagnostics IPO
Founded in 2000, Molbio Diagnostics develops and manufactures rapid diagnostic solutions for infectious and other diseases. Its flagship Truenat platform is a portable molecular testing system that delivers results in about an hour.
The company offers diagnostic tests for more than 30 diseases, including tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV. It also provides radiology, digital pathology, and breast health screening solutions through its subsidiaries and continues to expand its product portfolio through in-house research and development.
Molbio operates 6 manufacturing facilities in India and serves customers in over 90 countries, including hospitals, diagnostic laboratories, government health programmes, and international healthcare organisations. As of March 31, 2026, the company had 1,225 permanent employees.
Molbio Diagnostics IPO Reservation
For Molbio Diagnostics IPO, 35% of the issue has been reserved for retail investors. The table below shows the allocation across different investor categories.
|
Investor Category |
Shares Offered |
|---|---|
|
QIB Investors |
50% |
|
Retail Investors |
35% |
|
NII (HNI) Investors |
15% |
Molbio Diagnostics IPO Lot Size
Retail investors can apply for a minimum of 1 lot, which includes 18 shares costing ₹14,526 Maximum investment allowed for retail investors is 13 lots, which totals 234 shares and costs ₹1,88,838.
|
Application |
Lots |
Shares |
Amount (₹) |
|---|---|---|---|
|
Retail (Min) |
1 |
18 |
14,526 |
|
Retail (Max) |
13 |
234 |
1,88,838 |
|
S-HNI (Min) |
14 |
252 |
2,03,364 |
|
S-HNI (Max) |
68 |
1,224 |
9,87,768 |
|
B-HNI (Min) |
69 |
1,242 |
10,02,294 |
Molbio Diagnostics IPO Financial Performance
Molbio Diagnostics reported a PAT of ₹164 Cr as of 31 March 2026, up from ₹83 Cr in FY24. Over the past 3 years, the company’s PAT and PAT margin have grown steadily. All financial details are provided in the table below.
|
Period Ended |
31 Mar 2026 |
31 Mar 2025 |
31 Mar 2024 |
|---|---|---|---|
|
Revenue from Ops (₹ Cr) |
1445.69 |
1020.21 |
836.56 |
|
Total Income (₹ Cr) |
1,455.17 |
1,027.9 |
840.66 |
|
EBITDA (₹ Cr) |
328.24 |
256.64 |
185.09 |
|
EBITDA Margin (%) |
22.56 |
24.97 |
22.02 |
|
PAT (₹ Cr) |
164.14 |
138.58 |
83.54 |
|
PAT Margin (%) |
11.28 |
13.48 |
9.94 |
|
ROE (%) |
15.59 |
16.20 |
13.20 |
|
ROCE (%) |
17.55 |
20.98 |
15.80 |
Source: Molbio Diagnostics IPO RHP
Molbio Diagnostics IPO Peer Comparison from RHP
Molbio Diagnostics IPO has a decent EPS compared to its peers. Higher EPS is always considered better. Below is a brief comparison of Molbio Diagnostics IPO.
|
Company |
EPS (Diluted) |
P/E (x) |
|---|---|---|
|
Vijaya Diagnostic Centre |
16.79 |
81.02 |
|
Metropolis Healthcare |
9.19 |
63.72 |
|
Dr. Lal PathLabs |
30.20 |
62.20 |
|
Poly Medicure |
31.75 |
52.61 |
|
Molbio Diagnostics |
14.77 |
— |
As of 31 March 2026
Conclusion
Molbio Diagnostics IPO is drawing attention in the grey market ahead of its opening on 10 August 2026. While the company maintains healthy margins, its revenue and net profit declined in FY26. Before applying, compare its valuation, financials, and risks with listed peers.
All topics
Click the link, confirm the box next to sahi.com is checked — ignore any other results.